TLSA
Income statement / Annual
Last year (2022), Tiziana Life Sciences Ltd's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Tiziana Life Sciences Ltd's net income was -$16.21 M.
See Tiziana Life Sciences Ltd’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3,000.00
|
Cost of Revenue |
$51,000.00 |
$141,000.00 |
$89,764.00 |
$250,044.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Gross Profit |
-$51,000.00 |
-$141,000.00 |
-$89,764.00 |
-$250,044.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$3,000.00 |
Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
Research and Development
Expenses |
$12.96 M
|
$13.21 M
|
$6.36 M
|
$3.82 M
|
$5.24 M
|
$6.31 M
|
$3.65 M
|
$9.31 M
|
$1.24 M
|
$0.00
|
General & Administrative
Expenses |
$1.63 M
|
$855,000.00
|
$14.02 M
|
$6.21 M
|
$4.42 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$471,612.00
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$1.63 M
|
$855,000.00
|
$14.02 M
|
$6.21 M
|
$4.42 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$471,612.00
|
Other Expenses |
-$804,000.00 |
$13.31 M |
$11.89 M |
$6.38 M |
$3.48 M |
$3.57 M |
$4.33 M |
$2.33 M |
$1.97 M |
$0.00 |
Operating Expenses |
$14.59 M |
$27.37 M |
$32.27 M |
$10.19 M |
$9.45 M |
$11.14 M |
$8.99 M |
$12.76 M |
$4.02 M |
$471,612.00 |
Cost And Expenses |
$14.59 M |
$27.37 M |
$32.27 M |
$10.19 M |
$9.45 M |
$11.14 M |
$8.99 M |
$12.76 M |
$4.02 M |
$471,612.00 |
Interest Income |
$0.00 |
$0.00 |
$8,176.95 |
$1,311.17 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
$7,000.00 |
$176,000.00 |
$339,343.00 |
$94,403.00 |
$11,420.00 |
$12,162.00 |
$11,104.00 |
$26,667.00 |
$364,213.00 |
$0.00 |
Depreciation &
Amortization |
$51,000.00
|
$141,000.00
|
$91,000.00
|
$250,044.00
|
$15,226.00
|
$14,865.47
|
$9,870.45
|
$0.00
|
$1.18 M
|
-$9,893.97
|
EBITDA |
-$15.34 M
|
-$26.34 M
|
-$32.17 M
|
-$9.93 M
|
-$9.43 M
|
-$11.13 M
|
-$8.98 M
|
-$12.76 M
|
-$4.02 M
|
-$476,559.54
|
EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-158.85 |
Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-155.56
|
Total Other
Income/Expenses Net |
-$811,000.00
|
$717,000.00
|
-$331,166.44
|
-$94,403.94
|
-$9,456.96
|
-$9,000.00
|
-$9,000.00
|
-$18,000.00
|
-$234,000.00
|
$0.00
|
Income Before Tax |
-$15.40 M |
-$26.66 M |
-$30.07 M |
-$10.29 M |
-$9.46 M |
-$11.16 M |
-$9.00 M |
-$12.79 M |
-$5.56 M |
-$466,665.57 |
Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-155.56
|
Income Tax Expense |
$811,000.00 |
-$3.24 M |
-$2.34 M |
-$708,029.58 |
-$1.85 M |
-$2.01 M |
-$109,808.76 |
$0.00 |
-$93,388.12 |
$0.00 |
Net Income |
-$16.21 M |
-$23.42 M |
-$27.73 M |
-$9.58 M |
-$7.61 M |
-$9.15 M |
-$8.89 M |
-$12.79 M |
-$5.46 M |
-$466,665.57 |
Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-155.56 |
EPS |
-0.16 |
-0.24 |
-0.16 |
-0.0702 |
-0.0596 |
-0.0344 |
-0.019 |
-0.028 |
-0.0478 |
-0.0002 |
EPS Diluted |
-0.16 |
-0.24 |
-0.16 |
-0.0702 |
-0.0596 |
-0.0344 |
-0.019 |
-0.028 |
-0.0478 |
-0.0002 |
Weighted Average Shares
Out |
$101.53 M
|
$97.93 M
|
$169.07 M
|
$136.48 M
|
$127.55 M
|
$266.01 M
|
$467.96 M
|
$456.21 M
|
$114.33 M
|
$2.73 B
|
Weighted Average Shares
Out Diluted |
$101.53 M
|
$97.93 M
|
$169.07 M
|
$136.48 M
|
$127.55 M
|
$266.01 M
|
$467.96 M
|
$456.21 M
|
$114.33 M
|
$2.73 B
|
Link |
|
|
|
|
|
|
|
|
|
|